PT - JOURNAL ARTICLE AU - Landfors, Fredrik AU - Henneman, Peter AU - Chorell, Elin AU - Nilsson, Stefan K. AU - Kersten, Sander TI - Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk AID - 10.1101/2024.01.23.24301541 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.23.24301541 4099 - http://medrxiv.org/content/early/2024/04/15/2024.01.23.24301541.short 4100 - http://medrxiv.org/content/early/2024/04/15/2024.01.23.24301541.full AB - Background and Aims APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively pursued as pharmacological targets to treat dyslipidemia and reduce the risk of atherosclerotic cardiovascular disease. Here, we used human genetic data to compare the predicted therapeutic and adverse effects of APOC3, ANGPTL3, and ANGPTL4 inactivation.Methods We conducted drug-target Mendelian randomization analyses using variants in proximity to the genes associated with circulating protein levels to compare APOC3, ANGPTL3, and ANGPTL4 as drug targets. We obtained exposure and outcome data from large-scale genome-wide association studies and used generalized least squares to correct for linkage disequilibrium-related correlation. We evaluated five primary cardiometabolic endpoints and screened for potential side effects across 694 disease-related endpoints, 43 clinical laboratory tests, and 11 internal organ MRI measurements.Results Genetically lowering circulating ANGPTL4 levels reduced the odds of coronary artery disease (CAD) (odds ratio, 0.57 per s.d. protein [95%CI,0.47–0.70]) and type 2 diabetes (T2D) (odds ratio, 0.73 per s.d. protein [95%CI,0.57–0.94]). Genetically lowering circulating APOC3 levels also reduced the odds of CAD (odds ratio, 0.90 per s.d. protein [95%CI,0.82–0.99]). Genetically lowered ANGPTL3 levels via common variants were not associated with CAD. However, meta-analysis of deleterious variants revealed that ANGPTL3 inactivation protected against CAD (odds ratio, 0.79 per allele [95%CI, 0.69–0.90]). Analysis of lowered ANGPTL3, ANGPTL4, and APOC3 levels did not identify important safety concerns.Conclusion Human genetic evidence suggests that therapies aimed at reducing circulating levels of ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the risk of T2D.Key Question Does human genetics support that triglyceride-lowering drugs targeting ANGPTL3, ANGPTL4, and APOC3 will reduce the risk of cardiometabolic disease without causing side effects?Key Finding Genetically lowered circulating ANGPTL4 reduced coronary artery disease and type 2 diabetes risk. Genetically lowered ANGPTL3 and APOC3 also reduced coronary artery disease risk, but no impact on type 2 diabetes risk was observed.Take-home Message Human genetics suggest that ANGPTL3, ANGPTL4, and APOC3-lowering medications may prevent CAD. Medicines targeting ANGPTL4 may have added benefits for patients with type 2 diabetes.Graphical abstract summarizing the study’s methods and findings.Graphical abstract summarizing the overall study design. The ‘Key Findings’ figure provides a summary of the results categorized into three groups. The term ‘improves’ denotes a statistically significant association with a clinically relevant effect magnitude. The term ‘weak’ refers to a statistically significant association with no clinically significant effect. ‘ASCVD’ denotes atherosclerotic cardiovascular disease. ‘T2D’ denotes type 2 diabetes.Competing Interest StatementF.L. is a part-time employee of Lipigon Pharmaceuticals AB. S.K.N. is the chief executive officer of Lipigon. S.K. is a paid consultant for Lipigon.Funding StatementThis research received no specific grants from public or non-profit funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study analyzed scientific data that is available to the public, as detailed in Table 1 and Supplemental Table 1, where references to the specific datasets can be found. Analyses using individual-level access to the UK Biobank Resource were conducted under Application Number #148828. The Erasmus Rucphen Family study was approved by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands (64). All studies complied with the ethical standards outlined in the Helsinki Declaration.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDatabase identifiers and links to the public data sets are provided in Supplemental Table 1. Access to UK Biobank data is limited to authorized researchers who comply with data use policies to safeguard participant confidentiality. Interested researchers must apply to UK Biobank, adhering to an application process that ensures ethical and legal compliance in data handling. UK Biobank data set identifiers used for the analyses under Application Number #148828 are provided in the Supplemental Methods. The data from the Erasmus Rucphen Family study (ERF) cannot be shared publicly due to data protection laws. Access to this data is restricted to ensure participant confidentiality, aligning with legal and ethical obligations. Any request for access to the data for legitimate scientific purposes can be directed to the principal investigators of the ERF study, subject to a rigorous review process ensuring that all legal and ethical standards are met. The analyses in this manuscript were performed using the R programming language (v.4.2.1) with the packages coloc, cowplot, data.table, ggplot2, ggthemes, mungegwas, phewas, twosamplemr, wesanderson, writexl, and the Python programming language (v.3.8.16) using the packages numpy, pandas, and scipy. The LD matrix estimates were calculated using PLINK (v1.90b6.24).